ACP-196 (Acalabrutinib) in Combination with Pembrolizumab, for Treatment of Hematologic Malignancies

Trial Identifier: ACE-LY-005
Sponsor: AcertaPharma
Collaborator:
Merck
Start Date: February 2015
Primary Completion Date: July 2020
Study Completion Date: October 2025
Condition: Leukemia; Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
US, AZ Tucson, AZ, US, 85704
US, CA Los Angeles, CA, US, 90095
US, CO Denver, CO, US, 80218
US, DC Washington DC, DC, US, 20007
US, IL Niles, IL, US, 60714
US, MA Boston, MA, US, 2215
US, MN Rochester, MN, US, 55905-0001
US, NE Omaha, NE, US, 68198-7680
US, OH Columbus, OH, US, 43210
US, SC Greenville, SC, US, 29605
US, TN Nashville, TN, US, 37203
US, TX Dallas, TX, US, 75246
US, TX Houston, TX, US, 77030
US, TX San Antonio, TX, US, 78217
US, TX Tyler, TX, US, 75702
US, VA Fairfax, VA, US, 22031
US, VA Roanoke, VA, US, 24014
US, WA Vancouver, WA, US, 98684
US, WA Yakima, WA, US, 98902